Octreotide in the treatment of malignant thymoma - Case report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10414930" target="_blank" >RIV/00216208:11140/20:10414930 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/20:10414930

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JB24.58YoR" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=JB24.58YoR</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rpor.2020.08.012" target="_blank" >10.1016/j.rpor.2020.08.012</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Octreotide in the treatment of malignant thymoma - Case report

Popis výsledku v původním jazyce

Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated. Case report: A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months. Conclusion: We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake. (C) 2020 Greater Poland Cancer Centre

Název v anglickém jazyce

Octreotide in the treatment of malignant thymoma - Case report

Popis výsledku anglicky

Thymomas are the most common mediastinal tumors. Systemic therapy for patients with unresectable or recurrent thymomas is a challenging field in the current oncology research. There is some evidence that somatostatin analogs combined with corticosteroids may have a role in the treatment of advanced malignant thymoma; however, the role of these agents have not been fully evaluated. Case report: A 39-year-old man with metastatic thymoma was administered long-acting depot injection form of octreotide. Octreotide scan before the treatment initiation revealed low uptake. CT control after three months of the treatment revealed marked regression of pleural metastases, while the primary tumor mass remained stable. The treatment response was lasting for 9 months. Conclusion: We describe an interesting case of marked clinical and radiological response of advanced malignant thymoma to the treatment with octreotide in a heavily pre-treated patient, even though octreotide scan revealed low uptake. (C) 2020 Greater Poland Cancer Centre

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Reports of Practical Oncology and Radiotherapy

ISSN

1507-1367

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

4

Strana od-do

882-885

Kód UT WoS článku

000604399200006

EID výsledku v databázi Scopus

2-s2.0-85090753761